Additionally, please note that this drug has already been approved in the US, since May.
Now, onto the meat of this. If I'm not mistaken, erenumab is a cgrp inhibitor that made much fanfare a few months ago in New England Journal of Medicine when two studies found a clinical benefit in cgrp.
Basically healthcare providers are prescribing this if you failed the aforementioned therapies for migraine prophylaxis (since those are way cheaper).
On a funnier note, medical students such as myself have started referring to all of these new biologic drugs as "what-the-f*-umabs" since they all have weird names and we can't keep up with the rapid development of them.